Certain stockholders of AngioDynamics Inc. plan to offer for sale 2.35 million common shares in an underwritten secondary offering.

The selling stockholders will receive all of the net proceeds from this offering and no shares are being sold by the AngioDynamics.

Barclays Capital Inc. will act as underwriter for the offering.